As Alexion Pharmaceuticals INC (ALXN) Stock Price Rose, Premier Asset Managment LLC Has Lifted Position

October 2, 2018 - By Nellie Frank

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) LogoInvestors sentiment increased to 1.2 in Q2 2018. Its up 0.20, from 1 in 2018Q1. It is positive, as 31 investors sold ALXN shares while 169 reduced holdings. 62 funds opened positions while 178 raised stakes. 203.64 million shares or 1.34% more from 200.94 million shares in 2018Q1 were reported. Glenmede Com Na holds 0.01% or 11,859 shares in its portfolio. Reliance Trust Co Of Delaware stated it has 0.15% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Rathbone Brothers Public Ltd Com stated it has 0.01% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Johnson Fincl Group has invested 0.07% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Cibc Asset holds 0.04% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) or 55,003 shares. Raymond James Ser Advisors accumulated 27,476 shares. 127,000 are held by Ardsley Advisory Partners. Shine Inv Advisory Services Incorporated, a Colorado-based fund reported 419 shares. Credit Agricole S A holds 0% or 246 shares. Zeke Cap Advisors Limited Company has invested 0.03% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Sumitomo Mitsui Tru Hldg holds 0.1% or 681,884 shares in its portfolio. Federated Pa holds 0.01% of its portfolio in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) for 15,816 shares. Clearbridge Invests Ltd Limited Liability Company reported 4.49M shares or 0.46% of all its holdings. Webster Bancorp N A, Connecticut-based fund reported 7,000 shares. Nuveen Asset Limited Com has 6,247 shares.

Since April 30, 2018, it had 1 insider purchase, and 5 insider sales for $319,389 activity. Another trade for 1,862 shares valued at $220,703 was made by LAW ANNE-MARIE on Friday, June 8. Another trade for 1,645 shares valued at $194,982 was made by Goff Brian on Friday, June 8. ORLOFF JOHN J also sold $250,691 worth of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) shares. Clancy Paul J sold $687,148 worth of stock. Another trade for 1,466 shares valued at $173,765 was made by Franchini Indrani Lall on Friday, June 8.

Premier Asset Managment Llc increased its stake in Alexion Pharmaceuticals Inc (ALXN) by 355.85% based on its latest 2018Q2 regulatory filing with the SEC. Premier Asset Managment Llc bought 69,925 shares as the company’s stock rose 0.01% with the market. The institutional investor held 89,575 shares of the health care company at the end of 2018Q2, valued at $11.12 million, up from 19,650 at the end of the previous reported quarter. Premier Asset Managment Llc who had been investing in Alexion Pharmaceuticals Inc for a number of months, seems to be bullish on the $30.12B market cap company. The stock decreased 1.45% or $1.99 during the last trading session, reaching $135.13. About 1.42 million shares traded. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has declined 17.95% since October 2, 2017 and is downtrending. It has underperformed by 33.57% the S&P500.

Premier Asset Managment Llc, which manages about $425.14 million US Long portfolio, decreased its stake in Unitedhealth Group Inc (NYSE:UNH) by 48,625 shares to 925 shares, valued at $227,000 in 2018Q2, according to the filing.

More news for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) were recently published by: Seekingalpha.com, which released: “Alexion’s Soliris shows treatment effect in late-stage rare CNS disorder; shares up 5% premarket” on September 24, 2018. Seekingalpha.com‘s article titled: “Alexion to acquire Syntimmune” and published on September 26, 2018 is yet another important article.

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Ratings Coverage

Among 7 analysts covering Alexion Pharmaceuticals (NASDAQ:ALXN), 6 have Buy rating, 0 Sell and 1 Hold. Therefore 86% are positive. Alexion Pharmaceuticals had 11 analyst reports since April 20, 2018 according to SRatingsIntel. Credit Suisse maintained it with “Outperform” rating and $154 target in Tuesday, June 5 report. The stock of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) earned “Buy” rating by Citigroup on Tuesday, September 25. Stifel Nicolaus downgraded the stock to “Hold” rating in Tuesday, August 7 report. Piper Jaffray maintained Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) rating on Tuesday, May 8. Piper Jaffray has “Buy” rating and $17000 target. The stock has “Buy” rating by Stifel Nicolaus on Friday, April 27. The firm earned “Hold” rating on Tuesday, September 25 by Stifel Nicolaus. On Monday, April 30 the stock rating was maintained by Citigroup with “Buy”. The rating was maintained by Raymond James on Monday, April 23 with “Buy”. As per Tuesday, May 8, the company rating was maintained by Evercore. JP Morgan maintained Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) on Friday, July 27 with “Overweight” rating.

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>